SAN DIEGO, July 14, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, announces
the commercial availability of its new liquid biopsy test for
progesterone receptor (PR), which can be used for the detection and
monitoring of a key biomarker in the blood of patients with breast
cancer.
"The ability to detect PR expression in circulating tumor cells
(CTCs) complements Biocept's existing ER and HER2 assays for
biomarker analysis in breast cancer," said Veena Singh, M.D., Biocept's Senior Vice
President and Medical Director. "With the addition of PR
detection using our high sensitivity CTC platform, we offers liquid
biopsy assays for all NCCN Guideline®-based biomarkers pertinent to
the care of patients with breast cancer."
"We now have 14 commercially available liquid biopsy assays as
we execute on our initiative to expand our product menu of
non-invasive, cost-effective biomarker tests," said Biocept's
President and Chief Executive Officer Michael Nall. "Our goal is to offer tests
to detect and track all clinically actionable biomarkers listed in
the NCCN Guidelines® for solid tumors, which we believe is a
compelling value proposition for Biocept in the liquid biopsy
market."
Biocept's Target Selector™ PR expression test is performed on
CTCs utilizing fluorescently labeled antibodies. The Company's
liquid biopsy tests are performed in its CLIA-certified,
CAP-accredited laboratory located in San
Diego, California. To order a liquid biopsy test, please
contact Customer Service at 888-332-7729 or
customerservice@biocept.com.
About Progesterone Receptor (PR)
The progesterone
receptor (PR) is a protein found inside cells. Upon binding of the
steroid hormone progesterone, PR enters the nucleus and binds to
DNA, leading to the production of specific proteins. Clinically,
breast cancer cells can be tested for hormone sensitivity, also
referred as hormone receptor status, where tumor cells that stain
positive for PR and/or estrogen receptor (ER) suggest that the
patient may respond to a targeted therapy. About 80% of
breast cancers are hormone receptor positive.
About NCCN Guidelines®
The National Comprehensive
Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading
cancer centers devoted to patient care, research and education, is
dedicated to improving the quality, effectiveness and efficiency of
cancer care so that patients can live better lives. NCCN
offers a number of programs to give clinicians access to tools and
knowledge that can help guide decision-making in the management of
cancer. Over the past 25 years, NCCN has developed an integrated
suite of tools to improve the quality of cancer care. The
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
document evidence-based, consensus-driven management to ensure that
all patients receive preventive, diagnostic, treatment, and
supportive services that are most likely to lead to optimal
outcomes.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company
leverages its proprietary liquid biopsy technology to provide
physicians with clinically actionable information for treating and
monitoring patients diagnosed with cancer. Biocept's patented
Target Selector™ liquid biopsy technology platform captures and
analyzes tumor-associated molecular markers in both circulating
tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic options. For
additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
news release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to our ability to
identify specific clinical conditions or improve the outcomes of
cancer patients, the utility and effectiveness of our intellectual
property protections, the financial impact of new contracts, and
our ability to increase the number of products or services provided
or the value of the Company, such statements are forward-looking,
and are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risk factors as set forth
in our Securities and Exchange Commission (SEC) filings. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this news release. We do not plan to update any such
forward-looking statements and expressly disclaim any duty to
update the information contained in this press release except as
required by law. Readers are advised to review our filings with the
SEC at www.sec.gov
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocept-expands-commercial-offering-of-clinically-actionable-biomarker-assays-with-launch-of-liquid-biopsy-test-for-progesterone-receptor-detection-300488262.html
SOURCE Biocept, Inc.